Experimental Considerations in Headspace Gas Chromatography - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Experimental Considerations in Headspace Gas Chromatography
In this case study of amines, the authors discuss several parameters to be considered in developing a headspace GC method.


Pharmaceutical Technology
Volume 34, Issue 5, pp. 76-79

Conclusion


Figure 7
Three aspects of headspace method development were examined for a set of small basic amines. This compound class was chosen because these compounds are being used more frequently in the pharmaceutical industry in place of more traditional bases and because they often present problems in GC analyses because of their low sensitivity. It was shown that increasing the sample volume in the headspace vial does not always yield the desired increase in signal and that smaller amounts in the sammple vial can give the desired sensitivity. Specifically, the USP calls for solution volumes of 5 mL to be used, whereas these data show that 1 or 2 mL volumes can give equivalent signals using less material.


Figure 8
Equilibration time is another aspect of headspace method development that was examined. One must ensure that the sample has incubated long enough for all the solvents in the vial to achieve equilibrium with solvent in the liquid in the vial. If the sample does not reach equilibrium, the injection precision will vary from sample to sample. If the solution is in equilibrium with the gas phase, the injections will be consistent and precise. If the sample incubates too long, there is a risk of matrix degradation, which could add complexity to the residual-solvent analysis. The data showed that 15 min and often only 5 min were required for the residual amines to reach equilibrium. This finding is supported by the fact that upon longer incubation, there was no increase in signal. These data are in contrast to USP <467>, which sets a vial equilibrium time of 60 min. The data show that such an extended incubation is unnecessary; the time of analyses could be increased as much as 4–30 times and demonstrate the same sensitivity.


Figure 9
The final aspect of method development studied was multicomponent diluents. In some cases, it was possible to increase sensitivity by adding a small percentage of water or aqueous base to the sample diluents, as the water or aqueous base can aid in partitioning the solvents into the gas phase. In the case of triethylamine, the signal increased by 60% by using a diluent 80:20 ratio of DMSO:water instead of just DMSO. For allylamine, however, no combination of solvents yielded a signal higher than that with just using DMSO.

Many laboratories have generic residual-solvent methods that use a particular high-boiling solvent (i.e., DMSO, DMF, dimethlyacetamine, or n-methylpyrolidone) and a standard set of headspace conditions. These may work for many solvents/matrices; however, there are solvents that are more difficult to analyze, for example, the small organic amines that were studied in this work. This work has shown that by adjusting two of the GC headspace parameters (i.e., vial volume and equilibriation time), the consumption of sample and analysis time can be reduced. Finally, by trying different diluents (i.e., DMF versus DMSO for allylamine) and multicomponent diluents, containing a small amount of aqueous, the analysis of difficult analytes may be improved by enhanced sensitivity.

Laila Kott* is a senior scientist in analytical development, small molecules at Millennium Pharmaceuticals, 40 Landsdowne St., Cambridge, MA 02139,
or
, and Hong Ming Chen is a quality control chemist at Ash Stevens Inc., 18655 Krause St., Riverview, MI 48193.

*To whom all correspondence should be addressed.

Submitted: May 19, 2009; Accepted Sept. 18, 2009

References

1. USP 32–NF 27 General Chapter <467> "Residual Solvents" (2007).

2. ICH, Q3(R4) Impurities: Guideline for Residual Solvents (July 2007).

3. H. Takamatsu and S. Ohe, J. Chem. Eng. Data 48 (2), 277–279 (2003).

4. F. Banat et al., Chem. Eng. Process. 42, 917–923 (2003).

5. A. Naddaf and J. Balla, Chrom. Suppl. 51, S283–S287 (2000).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
7%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
Source: Pharmaceutical Technology,
Click here